source
- AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trialAstraZeneca reported that its oral relaxin agonist improved cardiac function in a subset of patients enrolled in a mid-stage heart‑failure study. The trial demonstrated measurable benefits for some…
- Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial missAstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…